8-K
IQVIA HOLDINGS INC. (IQV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
IQVIA HOLDINGS INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35907 | 27-1341991 |
|---|---|---|
| (State or other jurisdiction<br> <br>of incorporation) | (Commission<br> <br>File Number) | (IRS Employer<br> <br>Identification No.) |
| 2400 Ellis Rd.,<br> <br>Durham, North Carolina 27703 | ||
| --- | ||
| (Address of principal executive offices) |
Registrant’s telephone number, including area code: (919) 998-2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading<br> <br>Symbol | Name of Each Exchange<br> <br>on which Registered |
|---|---|---|
| Common Stock, par value $0.01 per share | “IQV” | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|---|
The Board of Directors (the “Board”) of IQVIA Holdings Inc. (the “Company”) appointed William G. Kaelin Jr., M.D. to the Board on November 5, 2025. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of “independent director.”
In connection with his appointment to the Board, Dr. Kaelin is expected to enter into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October 3, 2016 and is incorporated herein by reference. Dr. Kaelin will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described under “Director Compensation” in the Company’s proxy statement dated February 28, 2025, for its 2025 annual meeting of stockholders.
| Item 7.01. | Regulation FD Disclosure. |
|---|
The Company issued a press release announcing the appointment of Dr. Kaelin, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
|---|---|
| Exhibit No. | Description |
| --- | --- |
| 99.1 | Press release dated November 5, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025
| IQVIA HOLDINGS INC. | |
|---|---|
| By: | /s/ Eric Sherbet |
| Eric Sherbet | |
| Executive Vice President, General Counsel and Secretary |
EX-99.1
Exhibit 99.1
| Contact: | Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) |
|---|---|
| +1.973.541.3558 | |
| Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) | |
| +1.919.923.6785 |
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors
RESEARCH TRIANGLE PARK, N.C. – November 5, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Howard Hughes Medical Institute. In 2019, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein. He currently serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee.
“I am very pleased to welcome Bill to our board of directors,” said Ari Bousbib, chairman and CEO, IQVIA. “Bill is a world-renowned scientist and physician with deep expertise in oncology and biomedical innovation and will be an outstanding addition to our board.”
Dr. Kaelin is the recipient of numerous prestigious prizes and honors in addition to the Nobel Prize, including the Albert Lasker Basic Medical Research Award, the Wiley Prize in Biomedical Sciences from Rockefeller University, the Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center and the Canada Gairdner Internal Award. He is the author of hundreds of peer-reviewed publications and holds multiple patents related to cancer biology and hypoxia signaling.
Dr. Kaelin holds a Doctor of Medicine from Duke University School of Medicine and a Bachelor of Arts in Mathematics and Associate Bachelor in Chemistry from Duke University.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence^™^ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI^®^, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 91,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
IQVIAFIN
# # #
1